Osmotica Pharmaceuticals (NASDAQ:OSMT) Given New $12.00 Price Target at Royal Bank of Canada

Osmotica Pharmaceuticals (NASDAQ:OSMT) had its price objective upped by Royal Bank of Canada from $10.00 to $12.00 in a report published on Thursday morning, The Fly reports.

Other equities research analysts have also recently issued research reports about the stock. BidaskClub raised shares of Osmotica Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Thursday, June 25th. SunTrust Banks began coverage on shares of Osmotica Pharmaceuticals in a research note on Wednesday, March 18th. They issued a buy rating and a $8.00 price objective for the company. Zacks Investment Research cut shares of Osmotica Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, June 30th. ValuEngine cut shares of Osmotica Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, May 27th. Finally, Wells Fargo & Co cut shares of Osmotica Pharmaceuticals from an overweight rating to an equal weight rating and set a $4.00 price objective for the company. in a research note on Monday, March 23rd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Osmotica Pharmaceuticals presently has an average rating of Buy and an average target price of $8.63.

OSMT stock traded up $1.96 during midday trading on Thursday, reaching $8.96. The company had a trading volume of 1,000,273 shares, compared to its average volume of 403,309. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.26 and a quick ratio of 2.91. Osmotica Pharmaceuticals has a 1 year low of $2.70 and a 1 year high of $7.97. The company has a market capitalization of $327.67 million, a P/E ratio of -1.47 and a beta of 3.77. The firm has a 50-day moving average price of $6.04 and a 200-day moving average price of $5.30.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.07. Osmotica Pharmaceuticals had a negative net margin of 115.34% and a negative return on equity of 6.22%. The company had revenue of $48.65 million during the quarter, compared to analysts’ expectations of $43.76 million. On average, equities analysts predict that Osmotica Pharmaceuticals will post -0.67 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Osmotica Pharmaceuticals by 4.5% during the 1st quarter. BlackRock Inc. now owns 1,127,837 shares of the company’s stock valued at $3,586,000 after buying an additional 48,311 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in Osmotica Pharmaceuticals by 79,121.7% in the 1st quarter. Sunbelt Securities Inc. now owns 1,054,441 shares of the company’s stock worth $5,274,000 after purchasing an additional 1,053,110 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Osmotica Pharmaceuticals by 290.0% in the 4th quarter. Renaissance Technologies LLC now owns 510,112 shares of the company’s stock worth $3,566,000 after purchasing an additional 379,300 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Osmotica Pharmaceuticals by 88.7% in the 1st quarter. Acadian Asset Management LLC now owns 328,836 shares of the company’s stock worth $1,046,000 after purchasing an additional 154,541 shares in the last quarter. Finally, Wedge Capital Management L L P NC raised its holdings in Osmotica Pharmaceuticals by 49.3% in the 1st quarter. Wedge Capital Management L L P NC now owns 303,594 shares of the company’s stock worth $965,000 after purchasing an additional 100,219 shares in the last quarter. Institutional investors own 14.37% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

See Also: What is the LIBOR?

The Fly

Analyst Recommendations for Osmotica Pharmaceuticals (NASDAQ:OSMT)

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.